The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients

BACKGROUND: Prednisone (PDN) in juvenile dermatomyositis (JDM), alone or in association with other immunosuppressive drugs, namely methotrexate (MTX) and cyclosporine (CSA), represents the first-line treatment option for new onset JDM patients. No clear evidence based guidelines are actually availab...

Descripción completa

Detalles Bibliográficos
Autores principales: Giancane, Gabriella, Lavarello, Claudio, Pistorio, Angela, Oliveira, Sheila K., Zulian, Francesco, Cuttica, Ruben, Fischbach, Michel, Magnusson, Bo, Pastore, Serena, Marini, Roberto, Martino, Silvana, Pagnier, Anne, Soler, Christine, Staņēvicha, Valda, Ten Cate, Rebecca, Uziel, Yosef, Vojinovic, Jelena, Fueri, Elena, Ravelli, Angelo, Martini, Alberto, Ruperto, Nicolino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6530070/
https://www.ncbi.nlm.nih.gov/pubmed/31118099
http://dx.doi.org/10.1186/s12969-019-0326-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6530070/
https://www.ncbi.nlm.nih.gov/pubmed/31118099
http://dx.doi.org/10.1186/s12969-019-0326-5

Ejemplares similares